Announcement PDF RNS Number : 2359J Shield Therapeutics PLC 18 December 2020 Shield Therapeutics plc ("Shield" or the "Group" or the "Company") Grant of share options to the Chief Executive Officer London, UK, 18 December 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that on 18 December 2020 it granted share awards in the form of options over ordinary shares in the capital of the Company ("Ordinary Shares") under Shield Therapeutics Retention and Performance Share Plan ("RPSP"). In accordance with the requirements of the EU Market Abuse Regulations the following options have been granted to PDMRs: Name Tim Watts PDMR and CEO Option Plan RPSP Number of Ordinary Shares under Option 625,000 Vesting Date Dependent on performance conditions outlined below vesting can occur up until 31 December 2021. These awards are subject to the following performance conditions: 1) 60% of the options granted (375,000) will vest if the Company's market capitalisation is at or above £175m for five (5) consecutive trading days at any time during 2021. The Company's current market capitalisation is c. £66.9m 2) The remaining 40% of the options granted (250,000) will vest if the Company's market value is at or above £300m for five (5) consecutive trading days at any time during 2021 Mr Watts currently holds 648,700 ordinary shares in the Company, representing 0.55% of the Company's issued share capital. 1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name 2. Reason for the notification a) Position/status Tim Watts Chief Executive Officer b) Initial notification/ Initial Notification amendment 3. Details of the Issuer a) Name Shield Therapeutics plc b) LEI code 213800G74QWY15FC3W71 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of financial instrument the Identification code Options over Ordinary Shares ISIN: GB00BYV81293 b) Nature of the transaction Grant of awards over Ordinary Shares under the Company's Retention and Performance Share Plan. c) Price(s) and volumes(s) 2020 RPSP Award d) Price (£) Volume 0.015 625,000 Aggregated information - Aggregate volume Awards granted over 625,000 shares in total - Price 1.5p exercise price e) Date of the transaction 18 December 2020 f) Place of the transaction Outside of trading venue For further information please contact: Shield Therapeutics plc Tim Watts, CEO Lucy Huntington-Bailey, Company Secretary and General Counsel Nominated Adviser and Joint Broker Peel Hunt LLP James Steel/Dr Christopher Golden Joint Broker finnCap Ltd Geoff Nash/Matt Radley/Alice Lane Financial PR & IR Advisor Walbrook PR Paul McManus/Lianne Cawthorne www.shieldtherapeutics.com +44 (0)20 7186 8500 +44 (0)19 1511 8500 +44 (0)20 7418 8900 +44 (0)20 7220 0500 +44 (0)20 7933 8780 or shield@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7584 391 303 About Shield Therapeutics plc Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHFFAFWAESSEFE